Home / Research / Department of
Renal Medicine

Laboratory of Biostatistics

Head
Annalisa
Perna
Head of laboratory
Renal Medicine
annalisa.perna@marionegri.it
Senior Advisor
No items found.

The Laboratory of Biostatistics of the Department of Renal Medicine provides statistical support to the design, conduct and analysis of randomized clinical trials, mainly in the field of diabetic and non-diabetic chronic renal disease, renal transplantation, dialysis and rare diseases. It is also involved in systematic reviews promoted by international networks. Data collection of quality of life and socio-economic factors in participants enrolled in clinical trials are also collected.

Advanced statistical tools are used:

  • to identify prognostic factors of subsequent clinical events
  • to perform a joint analysis of repeated measures of biomarkers and survival data
  • to achieve statistical matching of treated and control groups by means of the propensity score when randomization is unfeasible in observational studies.

RESEARCH AREAS

Randomized, double-blind DIABASI trial

The study is aimed at assessing the effect of 6-month Acetyl-L Carnitine therapy on arterial blood pressure, lipid and metabolic profile, and kidney function in 228 hypertensive patients with type 2 diabetes.

Randomized, double-blind PROCEED trial

The study is aimed at evaluating the effects of paricalcitol and salt intake in type 2 diabetic patients with proteinuric chronic diseases.

Randomized, multicenter, blinded endpoint ANSWER trial

The study is aimed at assessing the renal and humoral effects of sevelamer carbonate in patients with chronic kidney disease and residual proteinuria despite best available treatment.

Randomized, multicenter, blinded endpoint VALID trial

The study evaluates whether, at comparable blood pressure control, combined therapy with the ACE inhibitor Benazepril and the angiotensin II receptor blocker (ARB) Valsartan reduces progression to ESRD more effectively than Benazepril or Valsartan alone in high risk patients with type 2 diabetes and overt nephropathy.

Randomized, double-blind ALADIN 2 trial

The study is aimed at evaluating the effects of long-acting somatostatin (Octreotide LAR) therapy on disease progression in patients with autosomal dominant polycystic kidney disease and moderate to severe renal insufficiency.

Randomized, multicenter, blinded endpoint ATHENA trial

The study is aimed at comparing the incidence of biopsy-proven Chronic Allograft Nephropathy three years post-transplant in kidney recipients randomly allocated to MMF or AZA, after induction therapy with basiliximab and low-dose RATG, and sequential steroid and CsA withdrawal.

Randomized, multicenter, blinded endpoint ARCADIA trial

The study is aimed at evaluating whether at comparable blood pressure control, ACE inhibitor therapy more effectively than non RAS inhibitor therapy reduce cardiovascular morbidity and mortality in patients with chronic dialysis of more than six months and with left ventricular hypertrophy and/or arterial hypertension.

Prospective, cohort, multicenter study on the role of anti-PLA2R1 epitope

The study is aimed at evaluating the predictive role of anti-PLA2R1 epitope spreading from the immunodominant CysR domain to CTLD1 and CTLD7 domains in 117 consecutive, rituximab-treated patients with PLA2R1-related MN and nephrotic syndrome.

Head Unit
No items found.
Staff
Francesco
Peraro
Researcher
francesco.peraro@marionegri.it
Giovanni Antonio
Giuliano
Researcher
giovanniantonio.giuliano@marionegri.it
This is some text inside of a div block.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Codice:

International Consensus on Cardiopulmonary Resuscitation.

1205
Non ci sono pubblicazioni selezionate al momento.
Head
Annalisa
Perna
Head of laboratory
Renal Medicine
annalisa.perna@marionegri.it
Senior Advisor
No items found.

Related Laboratories

Tieniti aggiornato sulle novità dell'Istituto Mario Negri. 

Iscriviti alla newsletter
Pagina Italiano